Amarantus Bioscience Holdings Inc (AMBS) 0.0505 $AMBS
Amarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-Threatening Pediatric Severe Burns
PR Newswire - Mon Aug 08, 8:15AM CDT
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced the publication of a 16-subject clinical study of Engineered Skin Substitute ("ESS," or "Permaderm(TM)"
in children with life-threatening severe burns. In this study, ESS was compared with the standard of care (split-thickness autograft "AG" for treating full-thickness (dermal and epidermal layers of skin) life-threatening pediatric severe burns covering a total body surface area (TBSA) of 50% or greater. Amarantus' wholly-owned subsidiary Cutanogen Corporation is pursuing the development of ESS towards regulatory approval for the treatment of life-threatening severe burns. ESS has received orphan drug designation from the U.S. FDA in the treatment of full-thickness burns covering over 50% TBSA.
Amarantus Announces cGMP Manufacturing Readiness for Its Engineered Skin Substitute (ESS) Program at Lonza Walkersville
PR Newswire - Tue Jun 07, 7:40AM CDT
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that the current Good Manufacturing Practices (cGMP) manufacturing process for its Engineered Skin Substitute (ESS) program is now qualified at Lonza Walkersville, Inc., a premier contract manufacturer providing cell and tissue-based products for clinical development. ESS is a lab-grown, full-thickness skin graft made from a patient's own skin that is expanded ~100 fold in size to provide permanent wound coverage of large body surface areas, initially for use in treating life-threatening burns.
Amarantus Completes Sale of Diagnostics Division, Announces Fiscal Year 2015 and First Quarter 2016 Financial Results
PR Newswire - Fri Jun 03, 8:00AM CDT
Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced the closing of the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc. to Avant Diagnostics, Inc. (OTCQB: AVDX), and reported consolidated financial statements for fiscal year 2015, and for the first quarter of 2016.
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 5.80 (+0.03)
Amarantus Announces Upcoming Investor Presentations
PR Newswire - Fri May 27, 8:52AM CDT
Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that President & CEO Gerald E. Commissiong will be presenting at two upcoming investor conferences:
Avant Diagnostics Simultaneously Completes Acquisitions of Amarantus Diagnostics and Theranostics Health
GlobeNewswire - Thu May 12, 6:30AM CDT
-- Operations of Amarantus Diagnostics and Theranostics Health have consolidated into Avant Diagnostics (OTCQB:AVDX)
Retired American Burn Association President Dr. David Ahrenholz to Present on Engineered Skin Substitute (ESS) at the Vatican's Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact
PR Newswire - Mon Apr 25, 7:00AM CDT
Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, today announced that Retired American Burn Association President Dr. David Ahrenholz has been selected to present Engineered Skin Substitute for the treatment of life threatening severe burns at The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact being held April 28-30, 2016 at the Vatican. Dr. Ahrenholz will be presenting on April 30, 2016 during the "Rebuilding and Restoring the Human Body" session beginning at 10:10am local time.
Amarantus Announces Capital Infusion
PR Newswire - Thu Apr 21, 3:02PM CDT
Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, has entered into a Securities Purchase Agreement (the "SPA" with three existing institutional investors for the sale of an aggregate principal amount $1,500,000 (including 10% OID) 10% Senior Secured Convertible Promissory Notes due April 17, 2017 (the "Notes" and a warrant to purchase 1,350,000 shares of common stock (the "Warrant" in a private placement offering. Pursuant to the SPA, the investors agreed to purchase additional aggregate principal amount of $1,555,556 (including 10% OID) of Notes and Warrants to purchase 1,400,000 shares of common stock upon effectiveness of a registration statement (the "Registration Statement" registering the common stock underlying the Notes and Warrants or earlier as mutually agreed between the investors and the Company and an additional $1,388,889 (including 10% OID) of Notes and Warrants to purchase 1,250,000 shares of common stock on the 61st day after effectiveness of the Registration Statement or earlier as mutually agreed between the investors and the Company. The first funding tranche of $1.35M has been delivered to the Company, with the primary use of proceeds to finance the Company's development of the ESS program. The Company is required to file the Registration Statement by April 29th, 2016.
Amarantus Announces Cancellation of Special Meeting of Shareholders
PR Newswire - Tue Mar 22, 7:00AM CDT
Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that it has cancelled the special meeting of shareholders scheduled for March 29, 2016.
Amarantus Receives Orphan Drug Designation From the US FDA for Eltoprazine in the Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
PR Newswire - Wed Feb 10, 6:45AM CST
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that it has received orphan drug designation from the US FDA for Eltoprazine in the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). Amarantus published positive results from a Phase 2 initial proof-of-concept clinical study in February of 2015 in the journal Brain, and highlighted the publication of two independent peer-reviewed scientific publications describing the mechanism of action of eltoprazine for the treatment of PD LID in August of 2015 and December 2016.
Amarantus to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
PR Newswire - Tue Feb 09, 1:23PM CST
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that it will be a featured presenting company at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference which takes place on February 10-11, 2016 in New York City. The Company's presentation will be given on Wednesday, February 10, 2016 at 12:30 pm by Gerald E. Commissiong, President & CEO of Amarantus, in the OneMedMarket Venture Track. The presentation will provide an update on the Company's regulatory interactions with FDA. Amarantus' CEO will be available for one-on-one meetings at the conference.
Amarantus Requests Rare Pediatric Disease Designation from US FDA for MANF in the Treatment of Retinitis Pigmentosa
PR Newswire - Fri Feb 05, 7:30AM CST
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, announced that it has requested Rare Pediatric Disease Designation (RPDD) from the US Food and Drug Administration (FDA) for treating retinitis pigmentosa (RP) with MANF. MANF was previously granted orphan drug designation (ODD) by the US FDA in December 2014.
Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)
PR Newswire - Wed Feb 03, 8:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that its wholly-owned subsidiary Cutanogen Corporation has received two Intent to Grant a Patent notices from the European Patent Officer for Engineered Skin Substitute (ESS). The notices cover the parent patent application entitled "A method of producing a cultured skin device" and an associated divisional patent filing. Amarantus expects both patents to issue later in 2016, adding key elements to our strong barrier-to-entry strategy for this innovative technology.
Amarantus Bioscience Holdings awarded Chinese patent for MANF for the treatment of Parkinson's disease and other neurodegenerative conditions
M2 - Mon Feb 01, 3:46AM CST
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) reported on Friday the receipt of the Chinese patent entitled "Neurodegenerative Disorders" covering the use of MANF for the treatment of Parkinson's disease and other neurodegenerative conditions.
Placing Risk and Finding Opportunity in Volatility -- Analyst Reports on Amarantus Bioscience Holdings, Yanzhou Coal Mining, L S Starrett, and Issuer Direct
ACCESSWIRE - Fri Jan 29, 2:44PM CST
NEW YORK, NY - Friday, January 29, 2016
YZC: 5.82 (+0.21), ISDR: 7.25 (-0.25), SCX: 11.20 (+0.06)
Amarantus Announces Issuance of Chinese Patent Covering Use of MANF for the Treatment of Parkinson's Disease
PR Newswire - Fri Jan 29, 8:00AM CST
Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, today announced the issuance of Chinese patent number ZL2009801163060 entitled "Neurodegenerative Disorders" covering the use of MANF for the treatment of Parkinson's disease and other neurodegenerative conditions. The claims issued extend patent coverage for MANF protein therapy, gene therapy and cell therapy applications into 2029.
SeeThruEquity Issues Update on Amarantus BioScience Holdings, Inc. (OTCQX: AMBS) Highlighting Merger with Avant Diagnostics, Inc. (OTCQB: AVDX)
ACCESSWIRE - Thu Jan 28, 10:20AM CST
NEW YORK, NY / ACCESSWIRE / January 28, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on Amarantus BioScience Holdings, Inc. (OTCQX: AMBS).
Amarantus Announces $1M Investment
PR Newswire - Wed Jan 27, 2:30PM CST
Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, today announced the closing of a $1M investment from an investor introduced to the Company by International Infusion, LLC. The new investment comes in the form of Series H Convertible Preferred Stock and Warrants on the same terms as previously disclosed. As part of the agreement, the Company's 2 largest institutional investors have agreed to certain trading restrictions over the course of the next 7 weeks.
Where We Are Headed - Comprehensive Research on Amarantus Bioscience Holdings, Newcrest Mining, Ping An Insurance Group Co. of China, and THK
ACCESSWIRE - Wed Jan 20, 7:45AM CST
NEW YORK, NY / ACCESSWIRE / January 20, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Amarantus Bioscience Holdings Inc. (OTC: AMBS), Newcrest Mining Ltd. (OTC: NCMGY), Ping An Insurance Group Co. of China Ltd. (OTC: PNGAY) and THK Co. Ltd. (OTC: THKLY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Amarantus Enters Into Letter of Intent to Merge Diagnostics Business Unit Into Avant Diagnostics
PR Newswire - Tue Jan 19, 8:15AM CST
Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, and Avant Diagnostics (OTCQB: AVDX), a medical diagnostic technology company, today announced they have entered into a Letter of Intent (the "LOI" to merge an Amarantus wholly-owned subsidiary, Amarantus Diagnostics, into Avant Diagnostics. Under the terms of the LOI, upon execution of definitive merger agreements, Avant shall issue to Amarantus 80 million shares of common stock of Avant Diagnostics, representing approximately 45% of Avant's post-merger common stock, and 10 million additional shares of common stock upon achievement of certain sales milestones. Amarantus shall have the right to appoint two directors to the Avant Board of Directors, and will assist Avant in bolstering its product development and commercialization resources to accelerate the further development of the combined company's product pipeline. The transaction is expected to be finalized in the second quarter of 2016, and is subject to customary closing conditions.
Amarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-Threatening Pediatric Severe Burns
PR Newswire - Mon Aug 08, 8:15AM CDT
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced the publication of a 16-subject clinical study of Engineered Skin Substitute ("ESS," or "Permaderm(TM)"
in children with life-threatening severe burns. In this study, ESS was compared with the standard of care (split-thickness autograft "AG" for treating full-thickness (dermal and epidermal layers of skin) life-threatening pediatric severe burns covering a total body surface area (TBSA) of 50% or greater. Amarantus' wholly-owned subsidiary Cutanogen Corporation is pursuing the development of ESS towards regulatory approval for the treatment of life-threatening severe burns. ESS has received orphan drug designation from the U.S. FDA in the treatment of full-thickness burns covering over 50% TBSA. Amarantus Announces cGMP Manufacturing Readiness for Its Engineered Skin Substitute (ESS) Program at Lonza Walkersville
PR Newswire - Tue Jun 07, 7:40AM CDT
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that the current Good Manufacturing Practices (cGMP) manufacturing process for its Engineered Skin Substitute (ESS) program is now qualified at Lonza Walkersville, Inc., a premier contract manufacturer providing cell and tissue-based products for clinical development. ESS is a lab-grown, full-thickness skin graft made from a patient's own skin that is expanded ~100 fold in size to provide permanent wound coverage of large body surface areas, initially for use in treating life-threatening burns.
Amarantus Completes Sale of Diagnostics Division, Announces Fiscal Year 2015 and First Quarter 2016 Financial Results
PR Newswire - Fri Jun 03, 8:00AM CDT
Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced the closing of the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc. to Avant Diagnostics, Inc. (OTCQB: AVDX), and reported consolidated financial statements for fiscal year 2015, and for the first quarter of 2016.
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 5.80 (+0.03)
Amarantus Announces Upcoming Investor Presentations
PR Newswire - Fri May 27, 8:52AM CDT
Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that President & CEO Gerald E. Commissiong will be presenting at two upcoming investor conferences:
Avant Diagnostics Simultaneously Completes Acquisitions of Amarantus Diagnostics and Theranostics Health
GlobeNewswire - Thu May 12, 6:30AM CDT
-- Operations of Amarantus Diagnostics and Theranostics Health have consolidated into Avant Diagnostics (OTCQB:AVDX)
Retired American Burn Association President Dr. David Ahrenholz to Present on Engineered Skin Substitute (ESS) at the Vatican's Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact
PR Newswire - Mon Apr 25, 7:00AM CDT
Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, today announced that Retired American Burn Association President Dr. David Ahrenholz has been selected to present Engineered Skin Substitute for the treatment of life threatening severe burns at The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact being held April 28-30, 2016 at the Vatican. Dr. Ahrenholz will be presenting on April 30, 2016 during the "Rebuilding and Restoring the Human Body" session beginning at 10:10am local time.
Amarantus Announces Capital Infusion
PR Newswire - Thu Apr 21, 3:02PM CDT
Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, has entered into a Securities Purchase Agreement (the "SPA"
with three existing institutional investors for the sale of an aggregate principal amount $1,500,000 (including 10% OID) 10% Senior Secured Convertible Promissory Notes due April 17, 2017 (the "Notes" and a warrant to purchase 1,350,000 shares of common stock (the "Warrant" in a private placement offering. Pursuant to the SPA, the investors agreed to purchase additional aggregate principal amount of $1,555,556 (including 10% OID) of Notes and Warrants to purchase 1,400,000 shares of common stock upon effectiveness of a registration statement (the "Registration Statement" registering the common stock underlying the Notes and Warrants or earlier as mutually agreed between the investors and the Company and an additional $1,388,889 (including 10% OID) of Notes and Warrants to purchase 1,250,000 shares of common stock on the 61st day after effectiveness of the Registration Statement or earlier as mutually agreed between the investors and the Company. The first funding tranche of $1.35M has been delivered to the Company, with the primary use of proceeds to finance the Company's development of the ESS program. The Company is required to file the Registration Statement by April 29th, 2016. Amarantus Announces Cancellation of Special Meeting of Shareholders
PR Newswire - Tue Mar 22, 7:00AM CDT
Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that it has cancelled the special meeting of shareholders scheduled for March 29, 2016.
Amarantus Receives Orphan Drug Designation From the US FDA for Eltoprazine in the Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
PR Newswire - Wed Feb 10, 6:45AM CST
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that it has received orphan drug designation from the US FDA for Eltoprazine in the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). Amarantus published positive results from a Phase 2 initial proof-of-concept clinical study in February of 2015 in the journal Brain, and highlighted the publication of two independent peer-reviewed scientific publications describing the mechanism of action of eltoprazine for the treatment of PD LID in August of 2015 and December 2016.
Amarantus to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
PR Newswire - Tue Feb 09, 1:23PM CST
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that it will be a featured presenting company at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference which takes place on February 10-11, 2016 in New York City. The Company's presentation will be given on Wednesday, February 10, 2016 at 12:30 pm by Gerald E. Commissiong, President & CEO of Amarantus, in the OneMedMarket Venture Track. The presentation will provide an update on the Company's regulatory interactions with FDA. Amarantus' CEO will be available for one-on-one meetings at the conference.
Amarantus Requests Rare Pediatric Disease Designation from US FDA for MANF in the Treatment of Retinitis Pigmentosa
PR Newswire - Fri Feb 05, 7:30AM CST
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, announced that it has requested Rare Pediatric Disease Designation (RPDD) from the US Food and Drug Administration (FDA) for treating retinitis pigmentosa (RP) with MANF. MANF was previously granted orphan drug designation (ODD) by the US FDA in December 2014.
Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)
PR Newswire - Wed Feb 03, 8:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that its wholly-owned subsidiary Cutanogen Corporation has received two Intent to Grant a Patent notices from the European Patent Officer for Engineered Skin Substitute (ESS). The notices cover the parent patent application entitled "A method of producing a cultured skin device" and an associated divisional patent filing. Amarantus expects both patents to issue later in 2016, adding key elements to our strong barrier-to-entry strategy for this innovative technology.
Amarantus Bioscience Holdings awarded Chinese patent for MANF for the treatment of Parkinson's disease and other neurodegenerative conditions
M2 - Mon Feb 01, 3:46AM CST
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) reported on Friday the receipt of the Chinese patent entitled "Neurodegenerative Disorders" covering the use of MANF for the treatment of Parkinson's disease and other neurodegenerative conditions.
Placing Risk and Finding Opportunity in Volatility -- Analyst Reports on Amarantus Bioscience Holdings, Yanzhou Coal Mining, L S Starrett, and Issuer Direct
ACCESSWIRE - Fri Jan 29, 2:44PM CST
NEW YORK, NY - Friday, January 29, 2016
YZC: 5.82 (+0.21), ISDR: 7.25 (-0.25), SCX: 11.20 (+0.06)
Amarantus Announces Issuance of Chinese Patent Covering Use of MANF for the Treatment of Parkinson's Disease
PR Newswire - Fri Jan 29, 8:00AM CST
Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, today announced the issuance of Chinese patent number ZL2009801163060 entitled "Neurodegenerative Disorders" covering the use of MANF for the treatment of Parkinson's disease and other neurodegenerative conditions. The claims issued extend patent coverage for MANF protein therapy, gene therapy and cell therapy applications into 2029.
SeeThruEquity Issues Update on Amarantus BioScience Holdings, Inc. (OTCQX: AMBS) Highlighting Merger with Avant Diagnostics, Inc. (OTCQB: AVDX)
ACCESSWIRE - Thu Jan 28, 10:20AM CST
NEW YORK, NY / ACCESSWIRE / January 28, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on Amarantus BioScience Holdings, Inc. (OTCQX: AMBS).
Amarantus Announces $1M Investment
PR Newswire - Wed Jan 27, 2:30PM CST
Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, today announced the closing of a $1M investment from an investor introduced to the Company by International Infusion, LLC. The new investment comes in the form of Series H Convertible Preferred Stock and Warrants on the same terms as previously disclosed. As part of the agreement, the Company's 2 largest institutional investors have agreed to certain trading restrictions over the course of the next 7 weeks.
Where We Are Headed - Comprehensive Research on Amarantus Bioscience Holdings, Newcrest Mining, Ping An Insurance Group Co. of China, and THK
ACCESSWIRE - Wed Jan 20, 7:45AM CST
NEW YORK, NY / ACCESSWIRE / January 20, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Amarantus Bioscience Holdings Inc. (OTC: AMBS), Newcrest Mining Ltd. (OTC: NCMGY), Ping An Insurance Group Co. of China Ltd. (OTC: PNGAY) and THK Co. Ltd. (OTC: THKLY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Amarantus Enters Into Letter of Intent to Merge Diagnostics Business Unit Into Avant Diagnostics
PR Newswire - Tue Jan 19, 8:15AM CST
Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, and Avant Diagnostics (OTCQB: AVDX), a medical diagnostic technology company, today announced they have entered into a Letter of Intent (the "LOI"
to merge an Amarantus wholly-owned subsidiary, Amarantus Diagnostics, into Avant Diagnostics. Under the terms of the LOI, upon execution of definitive merger agreements, Avant shall issue to Amarantus 80 million shares of common stock of Avant Diagnostics, representing approximately 45% of Avant's post-merger common stock, and 10 million additional shares of common stock upon achievement of certain sales milestones. Amarantus shall have the right to appoint two directors to the Avant Board of Directors, and will assist Avant in bolstering its product development and commercialization resources to accelerate the further development of the combined company's product pipeline. The transaction is expected to be finalized in the second quarter of 2016, and is subject to customary closing conditions. 
